Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO
Sign Up to like & getrecommendations! Published in 2018 at "mAbs"
DOI: 10.1080/19420862.2017.1402997
Abstract: ABSTRACT Immunotherapy with short term infusion (STI) of monoclonal anti-GD2 antibody (mAb) ch14.18 (4 × 25 mg/m2/d; 8–20 h) in combination with cytokines and 13-cis retinoic acid (RA) prolonged survival in high-risk neuroblastoma (NB) patients.… read more here.
Keywords: risk; response; ch14 cho; high risk ... See more keywords
Association of regulatory- and helper-T- cells with inferior survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.10530
Abstract: 10530Background: Long-term infusion (LTI) of the anti-GD2 antibody (Ab) ch14.18/CHO in combination with interleukin-2 (IL-2) prolongs survival in patients (pts) with high-risk neuroblastoma compare... read more here.
Keywords: term infusion; long term; association regulatory; ch14 cho ... See more keywords